EA201991135A1 - COMBINED THERAPY BY ARGINASE INHIBITORS - Google Patents
COMBINED THERAPY BY ARGINASE INHIBITORSInfo
- Publication number
- EA201991135A1 EA201991135A1 EA201991135A EA201991135A EA201991135A1 EA 201991135 A1 EA201991135 A1 EA 201991135A1 EA 201991135 A EA201991135 A EA 201991135A EA 201991135 A EA201991135 A EA 201991135A EA 201991135 A1 EA201991135 A1 EA 201991135A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- combined therapy
- arginase inhibitors
- arginase
- inhibitors
- subjects
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2086—IL-13 to IL-16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Изобретение касается способов лечения или профилактики заболеваний у субъектов путем совместного введения им описанного здесь ингибитора аргиназы и описанной здесь композиции, содержащей иммунные клетки.The invention relates to methods for treating or preventing diseases in subjects by co-administering an arginase inhibitor described herein and a composition comprising immune cells described herein.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762559931P | 2017-09-18 | 2017-09-18 | |
PCT/US2017/060636 WO2018089490A1 (en) | 2016-11-08 | 2017-11-08 | Arginase inhibitor combination therapies |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201991135A1 true EA201991135A1 (en) | 2019-11-29 |
Family
ID=68653612
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201991135A EA201991135A1 (en) | 2017-09-18 | 2017-11-08 | COMBINED THERAPY BY ARGINASE INHIBITORS |
Country Status (1)
Country | Link |
---|---|
EA (1) | EA201991135A1 (en) |
-
2017
- 2017-11-08 EA EA201991135A patent/EA201991135A1/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12019501575A1 (en) | ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF | |
EA201890161A1 (en) | THERAPEUTIC COMPOSITIONS, COMBINATIONS AND APPLICATION METHODS | |
EA201790195A1 (en) | METHODS OF TREATING CANCER WITH THE USE OF TIGIT INHIBITORS AND ANTI-CANCER AGENTS | |
ZA202208792B (en) | Methods of treating and preventing graft versus host disease | |
EA201791516A1 (en) | METHODS OF COMBINED TREATMENT OF MALIGNANT TUMORS | |
EA201790142A1 (en) | TREATMENT OF LEUKEMIA INHIBITORS HISTONDEACETYLASE | |
EA201790273A1 (en) | FLAGELLIN COMPOSITIONS AND THEIR APPLICATION | |
EA202092456A3 (en) | COMBINATION THERAPY INCLUDING MDM2 INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR TREATMENT OF VARIOUS TYPES OF CANCER | |
EA201691866A1 (en) | TUMOR LYMPHOCYTES PERMITTING FOR ADAPTIVE CELL THERAPY | |
EA201692285A1 (en) | EZH2 INHIBITORS FOR TREATING LYMPHOMA | |
PH12019501010A1 (en) | Arginase inhibitor combination therapies | |
BR112017005598A2 (en) | peptidomimetic macrocycles and their uses | |
EA201591543A1 (en) | COMBINED THERAPIES FOR CANCER TREATMENT WITH THE APPLICATION OF EGFR-TKI MICRORNA AND INHIBITORS | |
EA201690039A1 (en) | RORC2 INHIBITORS AND METHODS OF THEIR APPLICATION | |
TR201901348T4 (en) | Pyrrolidinone derivatives as metap-2 inhibitors. | |
EA201692481A1 (en) | COMBINATION CONTAINING GLUCOCORTICOID AND EDO-S101 | |
EA201892287A1 (en) | PHARMACEUTICAL COMBINATIONS FOR CANCER TREATMENT | |
EA201792571A1 (en) | THERAPEUTIC APPLICATION OF L-4-CHLOROKINURENIN | |
EA201791933A1 (en) | INHIBITION OF OLIG2 ACTIVITY | |
EA201892297A1 (en) | METHODS FOR TREATING CHOLESTATIC AND FIBROTIC DISEASES | |
EA202091112A1 (en) | SOCRYSTALS, PHARMACEUTICAL COMPOSITIONS BASED ON THEIR BASED AND METHODS OF TREATMENT FOR THEIR APPLICATION | |
EA202090266A1 (en) | MPO INHIBITORS FOR MEDICAL USE | |
EA202092045A1 (en) | TREATMENT AND PREVENTION OF PREECLAMPSIA | |
MX2020002585A (en) | Hdac inhibitor in combination with immune checkpoint modulator for cancer therapy. | |
EA201991135A1 (en) | COMBINED THERAPY BY ARGINASE INHIBITORS |